D. Montani (Le Kremlin-Bicêtre, France), J. Aman (Amsterdam, Netherlands)
Long Non-coding RNA H19 in Right Ventricular Failure associated with Pulmonary Arterial Hypertension
J. Omura (Quebec city, Canada), K. Habbout (Quebec city, Canada), S. Martineau (Quebec city, Canada), S. Breuils-Bonnet (Quebec city, Canada), V. Nadeau (Quebec city, Canada), F. Potus (Kingston, Canada), S. L. Archer (Kingston, Canada), R. Paulin (Quebec city, Canada), S. Provencher (Quebec city, Canada), O. Boucherat (Quebec city, Canada), S. Bonnet (Quebec city, Canada)
|  |
An investigation of the origins of pulmonary artery lesion cells in pulmonary arterial hypertension rat models
H. Miwa (Chiba, Japan), S. Sakao (Chiba, Japan), H. Suzuki (Chiba, Japan), T. Kobayashi (Chiba, Japan), F. Kato (Chiba, Japan), T. Jujo (Chiba, Japan), R. Nishimura (Chiba, Japan), N. Tanabe (Chiba, Japan), K. Tatsumi (Chiba, Japan)
| |
Cell freehaemoglobin and pulmonary artery endothelial cell dysfunction
Q. Toe (London, United Kingdom), M. Mohd Ghazaly (London, United Kingdom), T. Issit (London, United Kingdom), S. Wort (London, United Kingdom), G. Quinlan (London, United Kingdom)
| |
Functional study of polymorphisms in the promoter region of the endothelin-1 gene in Pulmonary Arterial Hypertension
A. Baloira Villar (PONTEVEDRA, Spain), D. Valverde (PONTEVEDRA, Spain), M. Lago (PONTEVEDRA, Spain)
| |
Role of adenylate kinase 4 as a new metabolic regulator of pulmonary artery smooth muscle cells under hypoxia
M. Wujak (Giessen, Germany), T. Wilke (Giessen, Germany), A. Weiss (Giessen, Germany), M. Brosien (Giessen, Germany), C. Wu (Giessen, Germany), R. Schermuly (Giessen, Germany), H. Ghofrani (Giessen, Germany), W. Seeger (Giessen, Germany), F. Grimminger (Giessen, Germany), O. Pak (Giessen, Germany), N. Weissmann (Giessen, Germany)
| |
MiR-1-5p targets TGF-ßR1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension
M. Connolly (London, United Kingdom), S. Wort (London, United Kingdom), B. Garfield (London, United Kingdom), A. Crosby (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom), P. Kemp (London, United Kingdom)
| |
MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension
X. Sun (Amsterdam, Netherlands), M. Gomez-Puerto (Leiden, Netherlands), I. Schalij (Amsterdam, Netherlands), A. Vonk-Noordegraaf (Amsterdam, Netherlands), F. De Man (Amsterdam, Netherlands), P. Ten Dijke (Leiden, Netherlands), H. Bogaard (Amsterdam, Netherlands)
|  |
The interplay of VEGF-inducing/inhibiting and breathing induced cyclic stretch in regulating the integrity of the functional microvasculature-on-chip
S. Zeinali (Bern, Switzerland), T. Geiser (Bern, Switzerland), O. Guenat (Bern, Switzerland)
| |
NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension
B. Kinsella (Dublin, Ireland), E. Mulvaney (Dublin, Ireland), H. Reid (Dublin, Ireland)
| |
Caspase-1 triggers smooth muscle cell proliferation in hypoxic pulmonary hypertension
C. Udjus (Oslo, Norway), B. Halvorsen (Oslo, Norway), P. Aukrust (Oslo, Norway), G. Christensen (Oslo, Norway), O. Skjønsberg (Oslo, Norway), K. Larsen (Oslo, Norway)
| |
Differential expression of miRNAs present in plasma and contained within circulating microparticles in precapillary pulmonary hypertension.
J. Oto (Valencia, Spain), O. Tura-Ceide (Barcelona, Spain), V. Sánchez-López (Sevilla, Spain), J. Osorio (Barcelona, Spain), C. Bonjoch (Barcelona, Spain), D. Hervás (Valencia, Spain), E. Arellano (Sevilla, Spain), P. Medina (Valencia, Spain), I. Blanco (Barcelona, Spain), V. Peinado (Barcelona, Spain), R. Otero (Sevilla, Spain), J. Barberà (Barcelona, Spain)
| |
Alterations in circulating helper T-cells in idiopathic pulmonary arterial hypertension
D. van Uden (Rotterdam, Netherlands), M. Van Nimwegen (Rotterdam, Netherlands), T. Koudstaal (Rotterdam, Netherlands), P. Heukels (Rotterdam, Netherlands), J. Van Hulst (Rotterdam, Netherlands), K. Boomars (Rotterdam, Netherlands), R. Hendriks (Rotterdam, Netherlands), M. Kool (Rotterdam, Netherlands)
| |
Comparative analysis of the plasma metabolomics in rodent models of pulmonary hypertension and patients with IPAH shows different metabolic signatures
J. Zhao (Beijing, China), Y. He (Beijing, China), S. Guo (Beijing, China), Y. Yan (Beijing, China), Z. Wang (Beijing, China), J. Ye (Beijing, China), J. Zhang (Beijing, China), Y. Wang (Beijing, China), X. Pang (Kaifeng, China), Z. Jing (Beijing, China), Z. Han (Beijing, China)
| |
Implication of Enhancer of Zeste Homolog 2 in Pulmonary Arterial Hypertension
S. Bonnet (Québec, Canada), K. Habbout (Québec, Canada), J. Omura (Québec, Canada), R. Paulin (Québec, Canada), S. Provencher (Québec, Canada), O. Boucherat (Québec, Canada)
| |
Inhibition of Monoamine Oxidase A in pulmonary artery banding-induced right heart failure
E. Peters (Amsterdam, Netherlands), X. Sun (Amsterdam, Netherlands), S. Andersen (Aarhus, Denmark), J. Birkmose Axelsen (Aarhus, Denmark), I. Schalij (Amsterdam, Netherlands), W. Van Der Laarse (Amsterdam, Netherlands), A. Andersen (Aarhus, Denmark), H. Bogaard (Amsterdam, Netherlands), F. Handoko - De Man (Amsterdam, Netherlands), A. Vonk Noordegraaf (Amsterdam, Netherlands)
| |
Survivin inhibition as a potential target for pulmonary arterial hypertension
I. Blanco (Barcelona, Spain), M. Marquina (Barcelona, Spain), O. Tura-Ceide (Barcelona, Spain), V. Peinado (Barcelona, Spain), J. Barberà (Barcelona, Spain)
| |
Macitentan treatment improves the dysfunctional right ventricle in a sugen/hypoxic rat model of pulmonary hypertension
G. Murphy (Glasgow, United Kingdom), G. Jayasekera (Glasgow, United Kingdom), J. Mullin (Glasgow, United Kingdom), L. Gallagher (Glasgow, United Kingdom), Y. Dempsie (Glasgow, United Kingdom), D. Welsh (Glasgow, United Kingdom)
| |